HIMS & HERS HEALTH ($HIMS) posted quarterly earnings results for Q4 2025 on Monday, February 23rd. The company reported earnings of $0.07 per share, beating estimates of $0.05 by $0.02. The company also reported revenue of $617,820,000, missing estimates of $631,606,103 by $-13,786,103.
Stock price change since market close: -4.33%
You can see Quiver Quantitative's $HIMS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HIMS & HERS HEALTH Insider Trading Activity
HIMS & HERS HEALTH insiders have traded $HIMS stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 12 sales selling 358,028 shares for an estimated $18,741,061.
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 10 sales selling 240,771 shares for an estimated $12,677,531.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 6 sales selling 34,899 shares for an estimated $1,616,604.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 7 sales selling 18,387 shares for an estimated $883,013.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 2 sales selling 20,042 shares for an estimated $873,931.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 16,821 shares for an estimated $733,472.
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HIMS & HERS HEALTH Hedge Fund Activity
We have seen 237 institutional investors add shares of HIMS & HERS HEALTH stock to their portfolio, and 366 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FORERUNNER VENTURES MANAGEMENT, LLC removed 9,756,893 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $316,806,315
- FARALLON CAPITAL MANAGEMENT LLC removed 7,359,866 shares (-68.5%) from their portfolio in Q4 2025, for an estimated $238,974,849
- CAPITAL WORLD INVESTORS removed 4,460,282 shares (-23.7%) from their portfolio in Q4 2025, for an estimated $144,825,356
- RENAISSANCE TECHNOLOGIES LLC removed 4,278,843 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $138,934,032
- SRS INVESTMENT MANAGEMENT, LLC removed 4,000,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $226,880,000
- MORGAN STANLEY removed 3,346,864 shares (-46.0%) from their portfolio in Q4 2025, for an estimated $108,672,674
- TIDAL INVESTMENTS LLC removed 2,759,789 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $89,610,348
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HIMS & HERS HEALTH Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/04/2025
- B of A Securities issued a "Underperform" rating on 11/04/2025
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for HIMS & HERS HEALTH, check out Quiver Quantitative's $HIMS forecast page.
HIMS & HERS HEALTH Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 7 analysts offer price targets for $HIMS in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Daniel Grosslight from Citigroup set a target price of $16.5 on 02/09/2026
- Allen Lutz from B of A Securities set a target price of $21.0 on 02/09/2026
- Jonna Kim from TD Cowen set a target price of $20.0 on 02/09/2026
- David Larsen from BTIG set a target price of $60.0 on 02/02/2026
- Mark Mahaney from Evercore ISI Group set a target price of $33.0 on 01/12/2026
- Glen Santangelo from Barclays set a target price of $48.0 on 12/09/2025
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
